If disease-modifying therapies for conditions such as Huntington’s disease are to become reality, clinicians and researchers need validated biomarkers. Different biomarkers will be required to monitor disease development (or regression) in the clinic, and to support decision-making in the drug development process. For example, biomarkers can identify:
- Pharmacodynamic, efficacy, and target engagement
- Stratification within a target patient population
- Alternative tissue or pathway read-outs (surrogate biomarkers)
- Toxicity events
This webcast will focus on the establishment of a high-sensitivity immunoassay to detect mutant HTT. The speakers will discuss its performance across several assay platforms, and how to validate it using Good Laboratory Practices. This HTT immunoassay is part of Evotec’s longstanding practice of supporting biomarker assessment in cells, tissues, or animal models, in order to confirm that drugs achieve the right exposure, bind the desired target, and generate a pharmacological response.
For Research Use Only. Not For Use In Diagnostic Procedures.
Speakers
Chantal Bazenet
Evotec SE, Germany
Cell Biologist
Dr. Chantal Bazenet is a cell biologist with over 20 years of experience in drug discovery and biomarker research in both academic and pharmaceutical settings. She has long-standing experience in identifying and quantifying biofluid biomarkers of neurodegeneration and neuroinflammation and has established highly sensitive assays to quantify biomarkers in preclinical and cellular models and in clinical human biofluids (CSF, plasma).
Elena Vicentini
Aptuit Srl, an Evotec Company, Italy
Biotechnologist
Dr. Elena Vicentini is a biotechnologist with over 20 years of experience in drug discovery and development in pharmaceutical and CRO settings. She has considerable experience in the development and validation of ligand-binding assays following regulatory guidelines and subsequent use in sample analysis to support PK/TK of large molecules, anti-drug antibodies, and biomarker quantification for both preclinical and clinical studies.
Protein biology
- Protein quantitation
Durée:58min
Langue:English
Session 1:présenté(e) October 19, 2020
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?